Diabetic nephropathy is another name for diabetic kidney disease (DKD). Diabetes-related kidney disease is referred to as DKD. It alters the normal process of removing waste products and excess fluid from the body by affecting kidney function. In India, diabetic kidney disease (DKD) is more common. One of the key reasons for the increase in new cases is that DKD patients are often undiagnosed and untreated. A diagnostic marker that can detect a disease at an early stage can be an effective tool for slowing disease development and avoiding the worst disease-related outcomes. Investigate the factors that influence renal function and patient outcomes in DK disease. The study was carried out by the Department of Biochemistry at Nagpur’s Datta Meghe Medical College. A total of 300 people participated in the study, including 150 healthy controls and other study group contain 150 DKD patients. The subjects were divided into three categories: normo-albuminuria, micro-albuminuria, and macro-albuminuria. In each family, there are 50 patients. Biochemical markers such as HbA1c, Urea, Creatinine, uric acid, protein, Total Cholesterol, Triglyceride, eGFR, and UACR were measured using specific biochemical procedures.

The goal of this study was to see if galectin-3 and GDF-15 may be used as a biomarker in the early identification of DKD.  The research was conducted at Nagpur’s Datta Meghe Medical College’s Department of Biochemistry. A total of 300 people took part in the study, 150 of whom were safe controls and 150 of whom were DKD patients. The subjects were divided into three categories: normoalbuminuria, microalbuminuria, and macroalbuminuria. There are 50 patients in each home. Specific biochemical procedures were used to measure biochemical markers such as HbA1c, Urea, Creatinine, uric acid, protein, Total Cholesterol, Triglyceride, eGFR, and UACR. The researchers wanted to determine if galectin-3 and GDF-15 could be used as a biomarker for DKD early identification. To validate galectin-3 and GDF-15’s potential as a potential predictive marker for use in routine clinical practice, multi-center, multi-national, and multi-ethnic studies are needed. Future research is also needed to assess CKD awareness in a large community-based sample and establish a CKD awareness model for both elevated patients and the general community in order to promote early detection, better treatment, and creative care. To generalise the finding of anaemia in DKD patients, we also suggest broad epidemiological studies with a comparable control group.